Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2009
Completed
1
33.3%
No Longer Available
1
33.3%
Recruiting
1
33.3%
No approval data available
- DelveInsight's 2025 pipeline report reveals 18+ active companies developing 20+ cancer cachexia therapies, addressing a critical unmet need in oncology care. - Key developments include Endevica Bio's TCMCB07 entering Phase II trials and CSPC's JMT203 receiving FDA approval for US clinical studies. - Cancer cachexia affects up to 87% of pancreatic and gastric cancer patients and accounts for approximately 22% of cancer-related deaths. - The therapeutic landscape includes diverse mechanisms targeting growth factors, melanocortin receptors, and adrenergic pathways through various administration routes.
- Endevica Bio has dosed the first patient in a Phase 2 trial evaluating TCMCB07 (B07) to prevent weight loss and cachexia in stage 4 metastatic colorectal cancer patients undergoing chemotherapy. - The trial will enroll 100 patients across 20 sites, addressing a significant unmet medical need as there are currently no FDA-approved therapeutics for cancer cachexia. - Preclinical studies published in the Journal of Clinical Investigation demonstrated TCMCB07's ability to improve appetite and preserve lean and fat mass in rodent models without adding chemotherapy-related toxicities.
- Endevica Bio has received FDA authorization to begin a Phase 2 clinical trial of TCMCB07 (B07), a peptide designed to prevent weight loss in stage 4 metastatic colorectal cancer patients undergoing chemotherapy. - The trial will enroll 100 patients who will receive B07 before and during chemotherapy, targeting cachexia - a life-threatening wasting syndrome affecting millions of cancer patients worldwide. - TCMCB07, a melanocortin-3/4 antagonist peptide, has shown promising results in Phase 1 trials and preclinical studies, demonstrating its ability to preserve lean muscle mass and improve appetite in cancer treatment settings.
- Endevica Bio has established a new spin-off company, Abisati, dedicated to developing 710GO, a melanocortin-targeting peptide that demonstrated 7.5% weight loss in preclinical monkey studies. - The experimental drug showed promising results in obese monkeys, including a 20% reduction in daily caloric intake and improved food choices, with plans for Phase I trials in late 2025. - 710GO aims to differentiate itself from current GLP-1 medications by potentially offering weight loss benefits without common side effects like nausea and preventing post-treatment weight rebound.
- Cancer cachexia, a devastating wasting syndrome affecting up to 40% of cancer patients, is gaining recognition as a critical therapeutic target beyond traditional tumor-focused treatments. - Novel melanocortin-4 receptor antagonist TCMCB07 demonstrates promising results in animal studies, successfully crossing the blood-brain barrier and preserving body mass without significant adverse effects. - Research indicates targeting the central melanocortin system could revolutionize cancer treatment approaches, with potential applications extending to other chronic conditions like kidney disease and COPD.
